CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Clene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.29+0.19 (+6.13%)
Close on Oct 19, 2026
- Market cap
- $40.74M
- P/E (TTM)
- –
- Dividend yield
- –
Clene statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Clene | Industry median |
|---|---|---|
| Market Cap | $42.27M | $164.85M |
| Enterprise Value | $37.95M | $87.06M |
| PS Ratio | 214.58 | 3.60 |
Enterprise value
| Measure | Clene | Industry median |
|---|---|---|
| EV / Sales | 192.62 | 2.43 |
Income (trailing twelve months)
| Measure | Clene | Industry median |
|---|---|---|
| Revenue | $197.00K | $57.94M |
| Gross Profit | $138.00K | $90.47M |
| Operating Income | -$20.55M | -$21.44M |
| Pretax Income | -$39.52M | -$14.45M |
| Net Income | -$39.52M | -$22.46M |
| EBITDA | -$20.55M | -$16.91M |
| EPS (Diluted) | -$3.48 | -$0.83 |
Margins
| Measure | Clene | Industry median |
|---|---|---|
| Gross Margin | 70.1% | 52.3% |
| Operating Margin | -10432.0% | -44.5% |
| Pretax Margin | -20059.9% | -13.0% |
| Profit Margin | -20059.9% | -39.2% |
| EBITDA Margin | -10432.0% | -31.3% |
Returns
| Measure | Clene | Industry median |
|---|---|---|
| Return on Assets (ROA) | -175.0% | -41.0% |
| Return on Capital Employed (ROCE) | -113.0% | -37.8% |
Growth
| Measure | Clene | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -31.1% | 6.01% |
| Revenue Growth (3Y CAGR) | -24.9% | 2.25% |
| Revenue Growth (5Y CAGR) | -0.59% | 6.42% |
Balance sheet
| Measure | Clene | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.70M | $62.42M |
| Total Debt | $5.37M | $120.13M |
| Net Cash (Debt) | $4.33M | $15.68M |
| Net Cash Per Share | $0.34 | $0.66 |
| Equity (Book Value) | -$24.78M | $48.79M |
| Book Value Per Share | -$1.93 | $1.36 |
| Tangible Book Value | -$24.78M | $23.06M |
| Working Capital | $10.06M | $75.77M |
Financial position
| Measure | Clene | Industry median |
|---|---|---|
| Current Ratio | 3.07 | 3.30 |
| Quick Ratio | 2.01 | 2.39 |
| Interest Coverage | -7.13 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Clene | Industry median |
|---|---|---|
| Operating Cash Flow | -$15.91M | -$12.35M |
Efficiency
| Measure | Clene | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Inventory Turnover | 1.02 | 2.67 |
| Revenue Per Employee | $2.49K | $398.96K |
| Profits Per Employee | -$500.23K | -$703.34K |
| Employee Count | 79 | 74 |
Dividends and yields
| Measure | Clene | Industry median |
|---|---|---|
| Earnings Yield | -93.5% | -22.7% |
Shares
| Measure | Clene | Industry median |
|---|---|---|
| Shares Outstanding | 12,848,500 | 58,179,650 |
| Shares Change (YoY) | 35.4% | 11.1% |
| Shares Change (QoQ) | 8.49% | 0.54% |
| Float | 6,957,060 | 49,173,100 |
| Shares Held by Insiders | 45.9% | 11.6% |
| Shares Held by Institutions | 24.8% | 59.4% |
Taxes
| Measure | Clene | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Clene | Industry median |
|---|---|---|
| Altman Z-Score | -21.92 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Clene's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.